The serum concentration of vitamin B12 is increased in chronic myelogenous leukemia, and there is an associated increase in the in vitro binding of vitamin B12 by such sera (1, 2) . On the other hand, the vitamin B12 concentration in the white cells and tissues in chronic myelogenous leukemia is not elevated (2) . Mollin, Pitney, Baker, and Bradley (3) have demonstrated a delayed disappearance of cobalt58 labelled vitamin B12 from the plasma of patients with chronic myelogenous leukemia using an intravenous dose of 1.5 micrograms. It was the purpose of this study to measure plasma disappearance, tissue distribution, and excretion of a 4-microgram intravenous dose of cobalt60 labelled vitamin B12 in normal subjects and patients with chronic myelogenous leukemia. In vitro experiments would indicate that this dose exceeds the binding capacity of normal serum by about four fold, but is within the total binding capacity of chronic myelogenous leukemia serum (1, 2, 4) .
Using a 4-microgram dose, a clear-cut differentiation could be made between normal controls and patients with chronic myelogenous leukemia. METHODS 
A. Clinical material
The subjects chosen for normal controls in this study were hospitalized patients convalescing from cerebrovascular accidents. Two to four months had elapsed since the onset of hemiparesis. All were asymptomatic save for residual paralysis, and none had evidence of anemia, renal disease, liver disease, congestive heart failure or infection. The diagnosis of chronic myelogenous leukemia was well established in eight patients. At the time of study, four patients had received no anti-leukemic therapy, and four had received some form of anti-leukemic therapy from three weeks to six months previously. Also studied were two patients with myeloid metaplasia, one patient with chronic lymphatic leukemia, one patient with utes and 8 to 10 per cent at two hours ( Figure 1 ). Thereafter, the disappearance rate was slower ( Figure 2 ). Because of the small amount of radioactivity present in the plasma after 24 hours, it was not possible to determine the slope of the disappearance curve accurately. (Figure 3) .
3. Other. One patient with chronic lymphocytic leukemia showed normal plasma disappearance (Figure 3 ). Both patients with myeloid metaplasia showed a plasma disappearance which was intermediate between that of the normal subjects and the patients with chronic myelogenous leukemia ( Figure 3 ). External monitoring. External monitoring of normal subjects showed an increase in liver radioactivity throughout the period of observation. During the first 5 hours after injection, there was very little increase in counting rate over the liver, despite the fact that during this interval 90 per cent of the administered dose had left the plasma. From 5 to 48 hours, the counts over the precordium were constant, counts over the liver rose, and there was a consistent fall in counts over the spleen (Figure 4) . Patients with chronic myelogenous leukemia, having a slower plasma disappearance, had a smaller rise in counting rate over the liver ( Figure 5 ). No increase in concentration of radioactivity over enlarged spleens was found. Counting rates over organ sites in the patient with chronic lymphocytic leukemia with normal plasma disappearance were the same as in the normal subjects.
2. Red and white cells. Red and white cells from both normal subjects and patients with leukemia contained no radioactivity.
3. Post mortem. The radioactivity in the organs of two patients with chronic myelogenous leukemia were determined at post mortem. Patient T. L. was injected 9 days and patient E. M. 23 days before death. The liver contained 39 to 42 per cent of the administered dose, the spleen 8 to 11 per cent and the other viscera less than one per cent (Table II) . The concentration of radioactivity in the liver (counts per gram) was five to seven times greater than in spleen and other viscera.
C. Excretion
In the twenty-four hours after injection, normal subjects excreted 1 to 4 per cent of the administered dose in the urine, and chronic myelogenous leukemia patients, 0 to 2 per cent (Table I) . Seven to ten-day stool collections were made in two normal subjects and contained no radioactivity. Ten-day bile collections contained less than 2 per cent of the administered dose. Ascitic fluid from a patient with cirrhosis (E. M.) was collected at intervals up to two hours during the measurement of the plasma disappearance. The entire 11 liters of fluid contained no radioactivity despite the fact that 90 per cent of the cobalt60 labelled vitamin B12 had disappeared from the plasma within the twohour interval.
D. Serum vitamin B12 concentration
In three normal subjects, the concentration of vitamin B12 in the serum ranged from 364 to 530 micromicrograms per ml. Serum vitamin B12 levels were elevated in four patients with chronic myelogenous leukemia ranging from 2046 to 9266 micromicrograms per ml. No correlation was found between the leukocyte count and the vitamin B12 level. Thus, patient E. M., with a normal white cell count, had the highest serum concentration of vitamin B12. The serum concentration of vitamin B12 was 704 micromicrograms per ml. in E. D., a patient with myeloid metaplasia, and 2104 in E. M., a patient with cirrhosis.
DISCUSSION
The 4-microgram dose used in this study exceeds the total plasma vitamin B12 in the normal by about three fold. Because of the specific activity of the cobalt60 labelled vitamin B12 available, the administration of a dose which would not significantly elevate the plasma concentration, i.e., a tracer amount, would result in plasma counting rates not measurable by current techniques. Although the 4-microgram dose approaches a tracer amount in some of the chronic myelogenous leukemic patients, in the normal subjects the results may not be truly physiological because of the dosage employed.
In the normal subjects, intravenous vitamin B12
in the dosage used disappeared rapidly from the plasma in spite of minimal excretion in urine, stool, and bile. This decline in plasma concentration of cobalt°labelled vitamin B12 during the first two hours after injection is too rapid to be explained solely by mixing in extracellular fluid. Also, no radioactivity was recovered in ascitic fluid, although the patient with impaired liver function may not be completely comparable. The liver is thought to be the chief storage site of vitamin B12 (9, 10) and one might expect that the material would be taken up by the liver as it leaves the plasma. However, we found no concentration of radioactivity over this or any other organ site during the first five hours as measured by external monitoring. During this same period, direct sampling of erythrocytes and leukocytes revealed no measurable radioactivity. It is apparent that during the first five hours after injection, when virtually all of the material had left the plasma, no site of localization of the injected material was found with the techniques employed. A diffuse cellular uptake during this period could account for these observations. However, external monitoring data indicate that the liver concentrates cobalt60 labelled vitamin B12 and/or related compounds containing cobalt60 beginning five hours after injection and continuing throughout the period of observation. This increase would seem too large to be accounted for by the small amount of material remaining in the plasma. Furthermore, during this period (five hours to two days) counting rates over the spleen continued to fall at a time when plasma and precordium counts were stable, suggesting cellular release of the vitamin or a cobalt-containing intermnediate. Continued accumulation of the radioactivity in the liver was not due to an enterohepatic circulation, since negligible radioactivity was recovered in the bile.
The slow disappearance of vitamin B12 from the plasma of patients with chronic myelogenous leukemia probably reflects increased binding of this vitamin by the plasma (1, 2) . This increased binding capacity correlated with the clinical state of the disease. Since serum concentrations decrease towards normal following successful therapy (1, 2), it is likely that this plasma abnormality also may disappear during remission (patient B. L.). Increased binding capacity did not correlate with the level of the white count, consistent with the reports that increases in serum concentration of B12 do not correlate with the level of the white count (1, 2). The plasma disappearance curve can be used to estimate the daily plasma turnover of vitamin B12 in the leukemic patient. This is based on the assumption that the disappearance curve beginning at 24 hours, with a half time of 5 days, represents the physiological turnover of plasma vitamin B12. This is likely, since this part of the curve is exponential. Also, the added radiovitamin elevated the original serum concentration of vitamin B12 by less than 20 per cent, 24 hours after injection. Using this half time of five days, and knowing the original serum concentration of B12 and the plasma volume, the daily turnover rates in four leukemic patients were calculated, and ranged from 1.1 to 4.8 micrograms per 24 hours. This cannot be related to the normal, since the small amount of radioactivity in the normal plasma precludes calculation of daily turnover.
Although the serum from patients with chronic myelogenous leukemia binds increased amounts of vitamin B12, the leukemic tissues from such patients do not appear to do so. No radioactivity was found in the leukocytes of leukemic patients at any time External monitoring over leukemic spleens revealed no concentration of radioactivity during the entire experiment (1 to 33 days), despite the disappearance of the radio-vitamin from the plasma. In two patients, the absence of splenic concentration of radioactivity as measured by external monitoring was corroborated by actual measurement of organ radioactivity at post mortem.
One patient with chronic lymphocytic leukemia was studied. Serum concentrations of vitamin B12 in this disease have been reported to be normal (1, 2) . In vivo binding, as demonstrated by plasma disappearance, was normal in this patient. The serum concentration of vitamin B12 in patients with myeloid metaplasia has been reported to be somewhat elevated, although not as high as in chronic myelogenous leukemia (2) . Although both patients with myeloid metaplasia were found to have a delayed disappearance of cobalt60 labelled vitamin B12 from the plasma, patient V. R. closely approximated the normal. In this patient histochemical staining of the polymorphonuclear leukocytes showed a decrease in the alkaline phosphatase as found in chronic myelogenous leukemia (11) . However, by clinical criteria, this patient did not appear to have leukemia. It seems likely that these biochemical abnormalities may exist in varying degrees in this group of patients. It is of interest that the other patient with myeloid metaplasia, E. D., with a more delayed plasma disappearance, had a normal serum vitamin B12 level. Consistent with other reports (7) patient E. M. with cirrhosis had a high serum vitamin B12 level. However, this patient had a normal plasma disappearance. There have been reports of elevated serum concentrations of vitamin B12 in acute leukemia (12) ; unfortunately no such patients were available for the present study.
Mollin, Pitney, Baker, and Bradley (3) have recently described delayed plasma disappearance of an intravenous dose of 1.5 micrograms of cobalt58 labelled vitamin B12 in two patients with chronic myelogenous leukemia. It is difficult to compare our results because of the difference in the doses used. It is of interest that they have taken the 6-minute plasma sample as representative of 100 per cent of the injected dose. Our studies using both 1.5 (13) and 4 micrograms showed that 6 minutes following injection, 45 to 65 per cent of the dose had left the plasma in normal subjects and 15 to 34 per cent in the leukemic patients. These factors may explain the greater differences between the two groups of patients found in the present study.
The mechanism of the increased binding of vitamin B12 in the serum of chronic myelogenous leukemic patients is not known. Vitamin B12 is bound to the alpha fraction of serum globulin in both normal subjects and leukemic patients (1, 4) . Increases in the concentration of this protein have been reported in many diseases not accompanied by an elevation of serum vitamin B12 concentration (14) (15) (16) . Material liberated by chronic myelogenous leukemic white cells will bind vitamin B12 in vitro, and it has been suggested that this is the in vivo mechanism (2). However, the vitamin can be bound to normal white blood cells (17) as well as to other protein fractions. Further work is needed to clarify this problem.
In any case, the present study demonstrates a biochemical plasma abnormality in a disease which chiefly affects white cells. Other biochemical changes which have been described in leukemia, such as alterations in the concentrations of alkaline phosphatase (11) and histamine (18) , have been intracellular. This relatively simple method of demonstrating increased in vsivo binding of vitamin B12 may be useful clinically in differentiating myelogenous leukemia from leukemoid states.
SUMMARY AND CONCLUSIONS 1. Four micrograms of cobalt60 labelled vitamin B12 were injected intravenously into normal subjects and patients with chronic myelogenous leukemia, and its plasma disappearance, tissue distribution and excretion were determined.
2. A rapid decline in plasma radioactivity occurred in normal subjects, contrasted with a slow decline in patients with clinically active chronic myelogenous leukemia. Excretion in urine and stools was negligible.
3. External monitoring of normal subjects, showed an increase in liver radioactivity throughout the period of observation, which was not associated with a comparable fall in plasma radioactivity. No concentration of radioactivity was found in spleen or white cells of patients with leukemia.
4. The plasma of patients with active chronic myelogenous leukemia can bind increased amounts of vitamin B12 in sivo. This may aid in differentiating chronic myelogenous leukemia from leukemoid states. 5 . At the dosage level used, an increased binding of cobalt60 labelled vitamin B12 by chronic myelogenous leukemic tissue was not found.
